Blood News and Research

RSS

PanGenex releases statement on Omega-3 and Lipideme

PanGenex Corporation a global manufacturer and distributor of nutraceutical and dietary supplement products, today released a statement in response to the many inquiries about Omega-3 and Lipideme.

1 Apr 2010

Refinements to CTC-chip may better monitor how CTC levels react to prostate cancer treatment

Technical improvements to a microchip-based device for detecting and analyzing tumor cells in the bloodstream are revealing cellular differences that may reflect a tumor's aggressiveness and long-term response to treatment.

1 Apr 2010

Canadian Blood Services renews partnership with DDB Canada and OMD Canada

Canadian Blood Services has renewed its partnership with DDB Canada and OMD Canada; signing a new, three-year contract for strategic advertising and media management services. Both DDB and OMD will continue to help recruit and retain the next generation of blood donors in Canada, in addition to helping expand and diversify the OneMatch Stem Cell and Marrow Network.

1 Apr 2010

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.

1 Apr 2010

FDA accepts for review Abbott's novel diagnostic test for rapid detection of NGAL

A novel diagnostic test to rapidly detect neutrophil gelatinase-associated lipocalin (NGAL), an early biomarker that identifies patients at risk for acute kidney injury (AKI), has been accepted for review by the United States Food and Drug Administration. If approved, this would be the first test available for use in the United States for the detection of NGAL.

1 Apr 2010

Worker health checks reveal 50% men at risk of developing diabetes

Over the last one year 100,000 State Government financed worker health check ups have been conducted. The results have been an eye-opener. 800 workers after their check ups have been asked to consult their physicians immediately. These check ups included measurements of blood pressure, blood cholesterol, blood sugar and waist circumference. The workers were also questioned regarding their eating, drinking and exercising habits.

1 Apr 2010

Hormone ghrelin may improve appetite in gastric cancer patients

In gastric cancer patients who have had part or all of their stomach removed, the hormone ghrelin may lessen post-operative weight loss and improve appetite, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute.

1 Apr 2010

Cardiac CT can help identify and predict at risk heart attack patients

One of the largest research studies into cardiac computed tomography (CT), conducted at the University of Ottawa Heart Institute (UOHI), shows that the high-speed advanced imaging technology can identify and predict patients at risk for heart attack and death.

1 Apr 2010

Breastfeeding benefits expanded to cover mothers: Risk of diabetes reduced

Research has found a new benefit that mothers can obtain by breast feeding – decreased risk of type 2 diabetes. Benefits of breastfeeding for the baby have been cited for a long time now. In spite of this knowledge according to The Australian Breastfeeding Association there is a definite gap in awareness regarding health benefits that this simple yet effective practice can offer.

1 Apr 2010

New medicines to fight diseases of particular concern to African Americans

A recent article in The Triangle Tribune pointed to good news for members of the black community, highlighting new medicines in development to fight diseases of particular concern to African Americans.

1 Apr 2010

Hemosphere completes $9.3M venture capital financing

Hemosphere, Inc., a private medical device company, has completed a late round of venture capital financing totaling $9.3 million. The company has developed the HeRO® Vascular Access Device, which provides access for hemodialysis - the process of filtering waste products from blood when kidneys are in renal failure - similar to a conventional graft.

1 Apr 2010

Tanda Professional Restore light therapy now made available for at-home use

During a press conference yesterday, doctors and experts unveiled a groundbreaking medical device using the healing properties of light therapy for pain management and improving mobility. For the first time ever, a licensed medical device that delivers clinical levels of light therapy only previously available in a doctor's office, has now been made available for at-home use.

1 Apr 2010

Personalized online resource to help Canadians achieve healthy weight loss

A Heart and Stroke Foundation survey of almost 2,000 Canadians found that 62% reported intentionally losing five or more pounds over the past five years but failed to keep the weight off. And 70% of those who were overweight or obese regained all or even more pounds after their weight-loss efforts.

1 Apr 2010

Cord Blood America signs License and Cooperation Agreement with AXM Pharma in China

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that it has signed a License and Cooperation Agreement for the processing and storage of umbilical cord blood in China with AXM Pharma, Inc.

1 Apr 2010

FDA clears AdvanDx' 90 minutes protocol for C. albicans PNA FISH and C. albicans/C. glabrata PNA FISH tests

AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its C. albicans PNA FISH® and C. albicans/C. glabrata PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.

31 Mar 2010

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.

31 Mar 2010

IVAX Diagnostics reports net revenue of $4.5M for quarter ended December 31, 2009

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, reports its financial results for the fourth quarter and full year ended December 31, 2009.

31 Mar 2010

Cryo-Cell International, MOSI partner to develop educational exhibit on stem cells and regenerative science

Cryo-Cell International Inc., a global leader of innovative stem cell solutions and stem cell cryopreservation services, today announced plans to partner with Museum of Science & Industry (MOSI) in the development and launch of an interactive educational exhibit on stem cells and regenerative science. Cryo-Cell is one of the most established private family cord blood banks and is a pioneer in the stem cell industry.

31 Mar 2010

Panel of experts endorse effectiveness of Mirasol PRT System for preventing GVHD

CaridianBCT, a leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, today announced that a panel of medical and scientific experts have endorsed the effectiveness of the Mirasol® Pathogen Reduction Technology System for replacing gamma irradiation, the current standard of care for preventing transfusion-related Graft vs. Host Disease in platelet recipients.

31 Mar 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

Blood News and Research

PanGenex releases statement on Omega-3 and Lipideme

Refinements to CTC-chip may better monitor how CTC levels react to prostate cancer treatment

Canadian Blood Services renews partnership with DDB Canada and OMD Canada

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

FDA accepts for review Abbott's novel diagnostic test for rapid detection of NGAL

Worker health checks reveal 50% men at risk of developing diabetes

Hormone ghrelin may improve appetite in gastric cancer patients

Cardiac CT can help identify and predict at risk heart attack patients

Breastfeeding benefits expanded to cover mothers: Risk of diabetes reduced

New medicines to fight diseases of particular concern to African Americans

Hemosphere completes $9.3M venture capital financing

Tanda Professional Restore light therapy now made available for at-home use

Personalized online resource to help Canadians achieve healthy weight loss

Cord Blood America signs License and Cooperation Agreement with AXM Pharma in China

FDA clears AdvanDx' 90 minutes protocol for C. albicans PNA FISH and C. albicans/C. glabrata PNA FISH tests

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

IVAX Diagnostics reports net revenue of $4.5M for quarter ended December 31, 2009

Cryo-Cell International, MOSI partner to develop educational exhibit on stem cells and regenerative science

Panel of experts endorse effectiveness of Mirasol PRT System for preventing GVHD

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News